Facebook Pixel

Colon Cancer Study Is Stopped

Rate This

A late-stage study of the cancer drug Sutent as a treatment for colon cancer has been halted because the drug is not effective enough, the drug's manufacturer, Pfizer, announced Tuesday.

The study was designed to compare the use of a combination treatment of Sutent and a type of chemotherapy with use of the chemotherapy alone. Researchers found that the combination treatment was not more effective at extending survival without cancer progression.

There were no safety issues, according to Pfizer.

Sutent is approved in the United States for treatment of advanced kidney cancer and gastrointestinal cancer, the Associated Press reported.

Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy

Colon Cancer

Get Email Updates

Related Topics

Colon Cancer Guide


Have a question? We're here to help. Ask the Community.


Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!